صحة
قبل 8 ساعاتملخص الذكاء الاصطناعي
济川药业自主研发1.1类中药创新药小儿通便颗粒获批上市
济川药业自主研发的1.1类中药创新药小儿通便颗粒正式获得国家药品监督管理局上市批准,填补了国内儿童便秘专用中药空白。
中
中国新闻网2 د قراءة
济川药业自主研发的1.1类中药创新药小儿通便颗粒正式获得国家药品监督管理局上市批准,填补了国内儿童便秘专用中药空白。
China has upgraded its child medication supply and security mechanism after 12 years with a new policy from eight departments. The 'Implementation Opinions' aim to address issues in R&D, production, supply, and clinical use, ensuring safer and more effective medications for children.